Moreover, extending our investigation to pediatric CNS tumors, the expression data from the Primary Brain Tumor Atlas confirmed that EphA3 is not only prevalent in high-grade gliomas but also in a spectrum of other pediatric brain tumors suggesting the broader applicability of EphA3 targeted therapies across CNS malignancies (figure 1B). This evidence concerns the gene EPHA3 and central nervous system neoplasm.